Mesa Laboratories (NASDAQ:MLAB) Raised to Strong-Buy at Wall Street Zen

Mesa Laboratories (NASDAQ:MLAB) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

Several other research firms have also issued reports on MLAB. Weiss Ratings restated a “sell (d)” rating on shares of Mesa Laboratories in a research report on Thursday, January 22nd. Wells Fargo & Company increased their price objective on Mesa Laboratories from $83.00 to $94.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 4th. Finally, Zacks Research raised shares of Mesa Laboratories from a “strong sell” rating to a “hold” rating in a research note on Friday, January 9th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Mesa Laboratories currently has a consensus rating of “Reduce” and a consensus price target of $94.00.

Mesa Laboratories Stock Performance

Mesa Laboratories stock opened at $93.27 on Friday. The company has a quick ratio of 1.45, a current ratio of 1.94 and a debt-to-equity ratio of 0.86. The company has a market capitalization of $514.85 million, a PE ratio of 145.74 and a beta of 0.89. The firm has a fifty day simple moving average of $82.11 and a two-hundred day simple moving average of $74.93. Mesa Laboratories has a twelve month low of $55.45 and a twelve month high of $155.12.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings data on Tuesday, February 3rd. The medical instruments supplier reported $3.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.41 by $0.66. Mesa Laboratories had a return on equity of 22.02% and a net margin of 1.51%.The firm had revenue of $65.13 million for the quarter, compared to analysts’ expectations of $63.23 million. Research analysts expect that Mesa Laboratories will post 8 EPS for the current year.

Institutional Trading of Mesa Laboratories

Institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its position in shares of Mesa Laboratories by 1.2% during the first quarter. Royal Bank of Canada now owns 30,772 shares of the medical instruments supplier’s stock valued at $3,652,000 after purchasing an additional 353 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Mesa Laboratories during the 1st quarter valued at $335,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Mesa Laboratories by 4.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock worth $364,000 after buying an additional 143 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Mesa Laboratories by 3.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 19,977 shares of the medical instruments supplier’s stock worth $2,370,000 after buying an additional 685 shares during the period. Finally, AlphaQuest LLC increased its stake in shares of Mesa Laboratories by 9,667.7% in the 2nd quarter. AlphaQuest LLC now owns 6,056 shares of the medical instruments supplier’s stock worth $571,000 after acquiring an additional 5,994 shares in the last quarter. 90.60% of the stock is currently owned by hedge funds and other institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.